Table 2.

The imaging characteristics before and after treatment between the Tet group and the control group

	Tet	Control	P-Value
Samll nodule [M(P25, 75)]
Before administration	6.0(4.0, 8.0)	7.5(4.0, 10.0)	0.120
After administration	6.0(4.0, 8.0)	7.5(4.0, 10.0)	0.046
P -Value	0.206	0.710
PMF size [M(P25, 75)]
Before administration	1568.0(682.0, 2905.0)	2055.0(904.0, 2070.0)	0.790
After administration	1526.0(758.0, 2528.0)	2306.0(1243.0, 3722.0)	0.001
P -Value	0.210	0.000
Emphysema [M(P25, 75)]
Before administration	6.0 (6.0, 11.3)	8.0 (6.0, 18.0)	0.035
After administration	6.0 (6.0, 11.8)	12.0 (6.0, 18.0)	0.022
P -Value	0.059	0.016
Rate of increase in PMF size [M(P25, 75)]	-2.5(-26.3, 11.8)	21.9(5.81, 39.9)	0.001
Patients with stable PMF n(%)	40(70)	23(32.8)
Patients with progression PMF n(%)	17(30)	47(67.2)	0.000

Progression PMF was defined as an increase in size of ≥ 10% from baseline, and stable as an increase of <10% . PMF: progressive massive fibrosis